TITLE

INIMEX BEGINS CLINICAL STUDY OF INNATE DEFENSE REGULATOR

PUB. DATE
June 2009
SOURCE
Worldwide Biotech;Jun2009, Vol. 21 Issue 6, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Inimex Pharmaceuticals administered Innate Defense Regulator (IDR) IMX942 on April 27, 2009 to healthy volunteers enrolled in the phase 1 study with Health Canada. IMX942 is treatment for the reduction of bacterial infections and decrease of inflammation. Said trial aims to investigate the safety and biological effects of IDR drugs in human subjects. Also mentioned is the Series B loan syndicate led by Morningside Venture Investments Ltd. secured by Inimex.
ACCESSION #
40098102

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics